文章摘要
李灿锥 ,李朝晖 ,周强 ,罗志伟 ,陈丹.利拉鲁肽抑制TLR4/Myd88信号通路对糖尿病合并脑缺血损伤大鼠的神经保护作用[J].神经损伤功能重建,2020,15(12):699-702
利拉鲁肽抑制TLR4/Myd88信号通路对糖尿病合并脑缺血损伤大鼠的神经保护作用
Neuroprotective Effects of Liraglutide on Diabetic Rats with Ischemic Brain Injury by Inhibit⁃ing TLR4/Myd88 Signal Pathway
  
DOI:
中文关键词: 利拉鲁肽  糖尿病  脑缺血损伤  TLR4/Myd88信号通路
英文关键词: liraglutide  diabetes mellitus  ischemic brain injury  TLR4/Myd88 signal pathway
基金项目:
作者单位
李灿锥1 ,李朝晖2 ,周强2 ,罗志伟2 ,陈丹2 1. 惠州市中心人民 医院神经内科 2. 珠海市人民医院 神经内科 
摘要点击次数: 3381
全文下载次数: 4280
中文摘要:
      目的:探讨利拉鲁肽(Liraglutide)对糖尿病合并脑缺血损伤大鼠的神经保护作用及其可能的机制。 方法:SD大鼠36只随机分为3组:假手术组(Sham组)、糖尿病大脑中动脉缺血组(DM+MCAO组)和利拉 鲁肽干预组(Liraglutide组)。糖尿病模型造模完成后1周,各组给予相应干预1周,再进行MCAO模型造 模。MCAO造模24 h后进行神经功能缺损评分,TTC染色法进行脑梗死体积测定,Western Blotting法检测 Toll 样受体 4(TLR4)和髓样分化因子 88(Myd88)蛋白的表达,荧光实时定量 PCR 法检测核转录因子κB (NF-κB)p65 mRNA的转录水平,ELISA法检测炎症因子白细胞介素(IL)-1β、肿瘤坏死因子(TNF)-α的浓 度。结果:DM+MCAO组和Liraglutide组注射链脲佐菌素1周后血糖显著升高(P<0.05),Liraglutide组注 射利拉鲁肽干预1周后血糖显著降低(P<0.05)。与DM+MCAO组相比,Liraglutide组神经功能缺损评分 显著下降(P<0.05)、脑梗死体积显著降低(P<0.05)、TLR4和Myd88蛋白表达显著降低(P<0.05)、NF-κB p65 mRNA转录水平显著下降(P<0.05), IL-1β和TNF-α的水平显著降低(P<0.05)。结论:利拉鲁肽对糖 尿病合并脑缺血损伤有神经保护作用,其机制可能通过抑制TLR4/Myd88信号通路介导的炎症反应。
英文摘要:
      To explore the neuroprotective effects and potential mechanism of liraglutide on diabetic rats with ischemic brain injury. Methods: A total of 36 rats were randomly divided into the sham operation group (Sham group), diabetes mellitus and middle cerebral artery occlusion group (DM+MCAO group), and liraglutide treatment group (Liraglutide group). One week after establishing the diabetes mellitus model, each group was given its corresponding treatment for 1 week, and a cerebral ischemia (MCAO) model was then created. Twenty-four hours after development of the MCAO model, neurological behavior was evaluated by neurological deficit scores; infarct volume was analyzed with TTC staining; expression of TLR4 and Myd88 proteins was measured by Western Blotting; expression of NF-κB p65 mRNA was detected by real-time PCR; and concentrations of IL-1β and TNF-α were measured by ELISA. Results: Blood glucose of the DM+MCAO and Liraglutide groups significantly increased 1 week after injection of STZ (P<0.05), and blood glucose of the Liraglutide group significantly decreased 1 week after injection of liraglutide (P<0.05). Compared with that of the DM+MCAO group, the neurological deficit scores and infarct volume of the Liraglutide group significantly declined (P<0.05), protein expression of TLR4 and Myd88 significantly decreased (P<0.05), mRNA expression of NF-κB p65 significantly decreased (P<0.05), and concentrations of IL-1β and TNF-α significantly decreased (P< 0.05). Conclusion: Our data indicate that the liraglutide exerts neuroprotective effects on diabetic rats with ischemic brain injury possibly through inhibiting the inflammatory response mediated by the TLR4/Myd88 signal pathway.
查看全文   查看/发表评论  下载PDF阅读器
关闭